Fubotv earnings beat by $0.10, revenue topped estimates
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) announced Friday that it has entered into an amended and restated employment agreement with Dr. John Kastelein, the company’s chief scientific officer and director. The agreement, effective as of July 1, 2025, replaces a prior employment agreement dated November 18, 2022.
According to a statement included in the company’s SEC filing, the new agreement specifies that if Dr. Kastelein’s employment is terminated by the company without cause, he will be entitled to receive 12 months of his base salary, any earned or payable bonus, and a prorated bonus for the year in which the termination occurs.
The filing also outlines provisions related to a change in control. If Dr. Kastelein’s employment is terminated without cause at the request of a third party involved in a change in control within three months prior to such change, or if his employment is terminated without cause or by him for good reason during the 12 months following a change in control, he will receive the same severance payments and benefits. In addition, all of Dr. Kastelein’s time-based stock options and equity awards will fully vest and become exercisable or nonforfeitable as of the termination date, and the exercise period for certain vested options will be extended.
NewAmsterdam Pharma’s ordinary shares and warrants are listed on The Nasdaq Stock Market LLC under the symbols NAMS and NAMSW, respectively.
This article is based on a statement from the company’s press release included in a recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.